Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872
Debt
Debt-to-Equity RatioN/A
Current Ratio8.10
Quick Ratio8.09
Price-To-Earnings
Trailing P/E Ratio-4.78
Forward P/E Ratio-4.91
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales72.63
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book3.07
Profitability
EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-58.26%
Return on Assets-49.38%
Miscellaneous
Employees131
Outstanding Shares69,500,000
Market Cap$688.08 million
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme Inc (NASDAQ:EPZM) posted its quarterly earnings data on Thursday, August, 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.53) by $0.11. The biopharmaceutical company had revenue of $12 million for the quarter, compared to analyst estimates of $0.54 million. The company's quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.48) earnings per share. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
9 brokers have issued 12-month price objectives for Epizyme's stock. Their forecasts range from $12.00 to $27.00. On average, they anticipate Epizyme's share price to reach $22.40 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View Analyst Price Targets for Epizyme.
What is the consensus analysts' recommendation for Epizyme?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.
What are Wall Street analysts saying about Epizyme stock?
Here are some recent quotes from research analysts about Epizyme stock:
- 1. Cann analysts commented, "Epizyme’s Q2 loss per share of $0.42 was less than our estimated loss of $0.60. This primarily resulted from an unanticipated milestone payment of $10 million and lower than estimated operating expense of $42.3 million vs. our estimated $46.8 million. Importantly, the NDA for tazemetostat is now expected in H1 2019 rather than our prior expectation of year-end 2018. This results from Epizyme wanting to submit more mature data in the epithelioid sarcoma setting and wanting to have the clinical hold for tazemetostat resolved before filing with FDA." (8/2/2018)
- 2. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. The company is assessing its timeline for submitting a new drug application to the FDA for tazemetostat regarding follicular lymphoma. The company plans to file a first new drug application for tazemetostat with respect to epithelioid sarcoma in the fourth quarter of 2018. A potential approval for the candidate will be a significant boost to the company. Loss estimates have narrowed ahead of the company’s Q2 earnings release. Epizyme has a positive record of earnings surprises in recent quarters. Shares of the company have outperformed the industry in the year so far." (7/24/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks. Our price target of $25 on Epizyme is based on a probability-adjusted sum-of-parts NPV-DCF: $21 EZH2 (NHL + INI-) + $1 DOT1L (MLL-R) + $3 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller- than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc." (6/27/2018)
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include Reata Pharmaceuticals (RETA), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Xencor (XNCR), The Medicines (MDCO), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Myokardia (MYOK), PTC Therapeutics (PTCT), Opko Health (OPK), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT) and AnaptysBio (ANAB).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
- Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
- Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
- Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
- Jason Fredette, VP of Investor Relations
Has Epizyme been receiving favorable news coverage?
News articles about EPZM stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Epizyme earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Epizyme.
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.77%), BlackRock Inc. (6.19%), Jennison Associates LLC (3.14%), Redmile Group LLC (2.91%), Voya Investment Management LLC (1.70%) and Citadel Advisors LLC (1.17%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.
Which major investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Point72 Asset Management L.P., Peregrine Capital Management LLC, California Public Employees Retirement System, Alps Advisors Inc., Alps Advisors Inc. and Bailard Inc.. Company insiders that have sold Epizyme company stock in the last year include Matthew Ros and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.
Which major investors are buying Epizyme stock?
EPZM stock was purchased by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, BlackRock Inc., Citadel Advisors LLC, Opaleye Management Inc., Northern Trust Corp, Federated Investors Inc. PA, Spark Investment Management LLC and First Trust Advisors LP. View Insider Buying and Selling for Epizyme.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $10.45.
How big of a company is Epizyme?
Epizyme has a market capitalization of $688.08 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (NASDAQ EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
